metronidazole has been researched along with Propionic Acidemia in 3 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Propionic Acidemia: Autosomal recessive metabolic disorder caused by mutations in PROPIONYL-COA CARBOXYLASE genes that result in dysfunction of branch chain amino acids and of the metabolism of certain fatty acids. Neonatal clinical onset is characterized by severe metabolic acidemia accompanied by hyperammonemia, HYPERGLYCEMIA, lethargy, vomiting, HYPOTONIA; and HEPATOMEGALY. Survivors of the neonatal onset propionic acidemia often show developmental retardation, and intolerance to dietary proteins. Late-onset form of the disease shows mild mental and/or developmental retardation, sometimes without metabolic acidemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diodato, D | 1 |
| Olivieri, G | 1 |
| Pro, S | 1 |
| Maiorani, D | 1 |
| Martinelli, D | 1 |
| Deodato, F | 1 |
| Taurisano, R | 1 |
| Di Capua, M | 1 |
| Dionisi-Vici, C | 1 |
| Nashabat, M | 1 |
| Obaid, A | 1 |
| Al Mutairi, F | 1 |
| Saleh, M | 1 |
| Elamin, M | 1 |
| Ahmed, H | 1 |
| Ababneh, F | 1 |
| Eyaid, W | 1 |
| Alswaid, A | 1 |
| Alohali, L | 1 |
| Faqeih, E | 1 |
| Aljeraisy, M | 1 |
| Hussein, MA | 1 |
| Alasmari, A | 1 |
| Alfadhel, M | 1 |
| Rafique, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness of the Use of Carbaglu® in Patients With Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)[NCT02426775] | Phase 3 | 33 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for metronidazole and Propionic Acidemia
| Article | Year |
|---|---|
Evaluation of long-term effectiveness of the use of carglumic acid in patients with propionic acidemia (PA) or methylmalonic acidemia (MMA): study protocol for a randomized controlled trial.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Carnitine; Child; Clinical Trials, Phase III as To | 2019 |
2 other studies available for metronidazole and Propionic Acidemia
| Article | Year |
|---|---|
Axonal peripheral neuropathy in propionic acidemia: A severe side effect of long-term metronidazole therapy.
Topics: Adolescent; Child; Humans; Metronidazole; Peripheral Nervous System Diseases; Propionic Acidemia | 2018 |
Emerging trends in management of propionic acidemia.
Topics: Adolescent; Anti-Infective Agents; Biotin; Carnitine; Child; Child, Preschool; Diet, Protein-Restric | 2014 |